An interventional study of cryoablation procedure using the iCLAS Cryoablation System in Atrial Fibrillation, Atrial Flutter and Paroxysmal Atrial Fibrillation, sponsored by Adagio Medical. Terminated at 4 sites in 3 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Adagio Medical · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 255 studies in Atrial Fibrillation with a site in Netherlands — 33 open to participants now, 49 under way, 2 of them phase 3. Atrial Fibrillation · Netherlands.
Among the 255 studies in Atrial Fibrillation with a site in Netherlands, this one is the 149th largest by enrollment of the 192 interventional ones that give a count, is one of 11 that started in 2021, is one of 106 with no phase, and was the 199th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →33 of the 255 studies in Atrial Fibrillation with a site in Netherlands are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Netherlands, Belgium, Germany and 3 more countries
Ages 18+
Bayer · Sites in Netherlands, United States, Belgium and 5 more countries
Ages 18–85
Milestone Pharmaceuticals Inc. · Sites in Netherlands, United States, Canada
Ages 18+
Happitech BV · Sites in Netherlands, United States
Ages 22 min+
Novartis Pharmaceuticals · Sites in Netherlands, United States, Canada and 4 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
255 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 23 · Phase 3 33 · Phase 4 29
First in 2000; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 250 across the 192 interventional studies, 400 across the 63 observational. Of the 185 that completed or were terminated, 72 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
135 of 255 have an industry lead sponsor. The 10 most frequent:
Adagio Medical is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Adagio Medical has 4 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
13 of the studies in Atrial Fibrillation with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07779213Happitech BVDetection of Atrial Fibrillation Using PPG From Smartphone Cameras | 2026-11 |
| NCT06355063Pulse Biosciences, Inc.CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation | 2026-12-31 |
| NCT06106594Abbott Medical DevicesVOLT CE Mark Study | 2027-01 |
| NCT06808217Boston Scientific CorporationA Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation | 2027-04-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 255 studies in Atrial Fibrillation with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A prospective, single-arm, multi-center study designed to collect real world safety and performance data of the Adagio Medical iCLAS Cryoablation System in the treatment of drug refractory, recurrent, symptomatic, Paroxysmal Atrial Fibrillation (PAF), Persistent Atrial Fibrillation (PsAF), and Atrial Flutter (AFL).
This Post-Market Clinical Follow-up (PMCF) study continues collecting additional information about the Adagio Medical iCLAS™ Cryoablation System in real world clinical settings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all subjects will receive a cryoablation procedure with the iCLAS System and be followed up for 12-month
Device: cryoablation procedure using the iCLAS Cryoablation System
all subjects will receive a cryoablation procedure using the iCLAS Cryoablation System (catheter, stylets, and console) and warming balloon
Primary outcome - freedom from AF
Freedom from Atrial Fibrillation (AF) recurrence during the 12-months follow-up period.
Time frame: 12 months
Primary outcome - freedom from AF/AT/AFL
Freedom from Atrial Arrhythmia at 12-months
Time frame: 12 months
Primary outcome - freedom from Device/Procedure Related Adverse Events
Freedom from Device / Procedure Related Adverse Events during and after the ablation procedure through12-month follow up
Time frame: during procedure and up to 12-month follow up
Plan to share: No
Ran from Sep 2021 to primary completion in Jan 2025, 40 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adagio Medical